Common side effects of Atripla include: dizziness, insomnia, and skin rash. Other side effects include: drowsiness, lack of concentration, and abnormal dreams.  See below for a comprehensive list of adverse effects.
The most common side effects reported with this drug were psychiatric disorders, nervous system disorders, and gastrointestinal disorders.  During a clinical trial using the individual components, the most common side effects were diarrhea, nausea, headache, fatigue, dizziness, depression, insomnia, abnormal dreams, and rash.In general, the most common side effects associated with efavirenz in combination with other antiretroviral drugs of at least moderate severity included rash, dizziness, nausea, headache, and fatigue; the most significant side effects were nervous system symptoms, psychiatric symptoms, and rash.In general, the most common side effects associated with emtricitabine in combination with other antiretroviral drugs of mild to moderate severity included headache, diarrhea, nausea, and rash; mild and asymptomatic skin discoloration (hyperpigmentation on the palms and/or soles) occurred more often with emtricitabine than the control treatment.In general, the most common side effects associated with tenofovir in combination with other antiretroviral drugs were mild to moderate gastrointestinal events, including nausea, diarrhea, vomiting, and flatulence.
Elevated fasting cholesterol (greater than 240 mg/dL), elevated fasting triglycerides (greater than 750 mg/dL), altered serum glucose (less than 40 mg/dL or greater than 250 mg/dL), hyperglycemia (greater than 250 mg/dL), and elevated alkaline phosphatase (greater than 550 units/L) have been reported in up to 22%, 4%, up to 3%, up to 2%, and 1% of patients, respectively.Hypercholesterolemia and hypertriglyceridemia have also been reported during postmarketing experience with efavirenz.Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.Hypokalemia and hypophosphatemia may occur as a result of proximal renal tubulopathy.Hypokalemia, lactic acidosis, and hypophosphatemia have also been reported during postmarketing experience with tenofovir.
Very common (10% or more): Elevated fasting cholesterol (up to 22%)Common (1% to 10%): Anorexia, elevated fasting triglycerides, altered serum glucose, hyperglycemia, elevated alkaline phosphataseUncommon (0.1% to 1%): Increased appetiteEfavirenz:-Common (1% to 10%): Anorexia, hypertriglyceridemia-Uncommon (0.1% to 1%): Hypercholesterolemia-Postmarketing reports: Redistribution/accumulation of body fat (in areas such as back of neck, breasts, abdomen, retroperitoneum)Emtricitabine:-Common (1% to 10%): Hyperglycemia, hypertriglyceridemiaTenofovir:-Very common (10% or more): Hypophosphatemia-Uncommon (0.1% to 1%): Hypokalemia-Rare (less than 0.1%): Lactic acidosisCombination antiretroviral therapy:-Frequency not reported: Metabolic abnormalities (e.g., hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia, hyperlactatemia), redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance")
Common (1% to 10%): Diarrhea, nausea, elevated serum amylase, vomitingUncommon (0.1% to 1%): Dry mouthEmtricitabine or tenofovir:-Common (1% to 10%): Dyspepsia, abdominal pain, elevated pancreatic amylase, elevated serum lipaseEfavirenz:-Common (1% to 10%): Dyspepsia, abdominal pain, diarrhea, vomiting, nausea-Uncommon (0.1% to 1%): Pancreatitis-Postmarketing reports: Constipation, malabsorptionEmtricitabine:-Very common (10% or more): Diarrhea, nausea-Common (1% to 10%): Elevated amylase (including elevated pancreatic amylase), elevated serum lipase, vomiting, abdominal pain, dyspepsiaTenofovir:-Very common (10% or more): Diarrhea, vomiting, nausea-Common (1% to 10%): Abdominal pain, abdominal distension, flatulence-Uncommon (0.1% to 1%): Pancreatitis-Postmarketing reports: Increased amylase
Elevated serum amylase (greater than 175 units/L) has been reported in up to 8% of patients.Elevated pancreatic amylase (greater than 2 x ULN) and serum lipase (greater than 2 x ULN) have each been reported with emtricitabine or tenofovir in up to 3% of patients.Pancreatitis and abdominal pain have also been reported during postmarketing experience with efavirenz and tenofovir.
Serious psychiatric side effects associated with efavirenz have included severe depression, suicidal ideation, nonfatal suicide attempts, aggression, paranoia, and mania.Aggression, agitation, affect lability, psychosis, paranoia, and mania have also been reported during postmarketing experience with efavirenz.
Common (1% to 10%): Depression, anxiety, insomniaUncommon (0.1% to 1%): Decreased libidoEfavirenz:-Very common (10% or more): Insomnia (up to 16.3%)-Common (1% to 10%): Depression, anxiety, severe depression, abnormal dreams, nervousness, hallucination-Uncommon (0.1% to 1%): Suicidal ideation, nonfatal suicide attempts, aggression, paranoia, mania, psychosis, euphoric mood, affect/emotional lability, confusional state, agitation-Frequency not reported: Depersonalization, delirium-Postmarketing reports: Delusions, neurosis, psychosis-like behavior, completed suicideEmtricitabine:-Common (1% to 10%): Insomnia, abnormal dreams
Common (1% to 10%): Dizziness, headacheUncommon (0.1% to 1%): Incoherent speechEmtricitabine or tenofovir:-Common (1% to 10%): Paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy)Efavirenz:-Very common (10% or more): Nervous system symptoms (53%), dizziness (up to 28.1%)-Common (1% to 10%): Impaired concentration, somnolence, cerebellar coordination and balance disturbances, headache, disturbance in attention-Uncommon (0.1% to 1%): Convulsions, amnesia, abnormal thinking, ataxia, abnormal coordination, tremor, vertigo, tinnitus-Frequency not reported: Stupor-Postmarketing reports: Hypoesthesia, paresthesia, neuropathyEmtricitabine:-Very common (10% or more): Headache-Common (1% to 10%): DizzinessTenofovir:-Very common (10% or more): Dizziness-Common (1% to 10%): Headache
Nervous system symptoms of any grade and regardless of causality (53%) included dizziness, insomnia, impaired concentration, somnolence, abnormal dreams, hallucinations, amnesia, agitation, euphoria, depersonalization, confusion, abnormal thinking, and stupor during clinical trials of efavirenz in combination with other antiretroviral agents.  These symptoms were mild in 33.3%, moderate in 17.4%, and severe in 2% of patients; generally began the first or second day of therapy and often resolved after 2 to 4 weeks.  Therapy was discontinued in 2.1% of patients due to these side effects.Abnormal coordination, ataxia, cerebellar coordination and balance disturbances, convulsions, tremor, tinnitus, and vertigo have also been reported during postmarketing experience with efavirenz.
Rashes associated with efavirenz were usually mild-to-moderate maculopapular skin eruptions.  The median time to onset of rash was 11 days.  In most patients who continued therapy, the rash resolved within 1 month.  Treatment was discontinued in 1.7% of patients due to rash.There was limited experience using efavirenz in patients who previously discontinued other nonnucleoside reverse transcriptase inhibitors due to rash.  In 19 such patients formerly on nevirapine, about half developed a mild to moderate rash; 2 of those patients discontinued efavirenz because of the rash.Erythema multiforme, pruritus, photoallergic dermatitis, and Stevens-Johnson syndrome have also been reported during postmarketing experience with efavirenz.  Rash has also been reported during postmarketing experience with tenofovir.
Common (1% to 10%): Rash event (including rash, exfoliative rash, generalized rash, macular rash, maculopapular rash, pruritic rash, vesicular rash)Emtricitabine or tenofovir:-Common (1% to 10%): Rash event (including rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, pustular rash, allergic reaction)Efavirenz:-Very common (10% or more): Skin rash of any grade (up to 26.3%), grade 2 rash (diffuse maculopapular rash, dry desquamation; 14.7%), grade 1 rash (erythema, pruritus; 10.7%)-Common (1% to 10%): Pruritus-Uncommon (0.1% to 1%): Grade 3 rash (vesiculation, moist desquamation, ulceration), grade 4 rash (erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, necrosis requiring surgery, exfoliative dermatitis)-Rare (less than 0.1%): Photoallergic dermatitis-Frequency not reported: Nail disorders, skin discoloration, leukocytoclastic vasculitisEmtricitabine:-Common (1% to 10%): Vesiculobullous rash, pustular rash, maculopapular rash, rash, pruritus, urticaria, skin discoloration (palmar-plantar hyperpigmentation)-Postmarketing reports: AngioedemaTenofovir:-Very common (10% or more): Rash-Rare (less than 0.1%): Angioedema
Common (1% to 10%): FatigueFrequency not reported: Increased body weightEmtricitabine or tenofovir:-Common (1% to 10%): Fever, pain, back painEfavirenz:-Common (1% to 10%): Pain, fatigue-Uncommon (0.1% to 1%): Flushing-Frequency not reported: False-positive urine cannabinoid test results-Postmarketing reports: Contraceptive failure (with an implantable hormonal contraceptive), astheniaEmtricitabine:-Common (1% to 10%): Pain, astheniaTenofovir:-Very common (10% or more): Asthenia-Frequency not reported: Higher 1,25 vitamin D levels
False-positive urine cannabinoid test results have been reported with some screening assays in uninfected and HIV-infected patients receiving efavirenz.Flushing and asthenia have also been reported during postmarketing experience with efavirenz and tenofovir, respectively.
Common (1% to 10%): Sinusitis, upper respiratory tract infections, nasopharyngitisEmtricitabine or tenofovir:-Common (1% to 10%): Increased cough, pneumonia, rhinitisEfavirenz:-Postmarketing reports: DyspneaTenofovir:-Postmarketing reports: Dyspnea
Elevated AST (greater than 180 units/L in males and 170 units/L in females) and ALT (greater than 215 units/L in males and 170 units/L in females) have been reported in 3% and 2% of patients, respectively.AST and ALT elevations were reported more often in patients who were coinfected with hepatitis B or C than in patients without coinfection.Elevated bilirubin (greater than 2.5 times the upper limit of normal [2.5 x ULN]) has been reported with emtricitabine or tenofovir in up to 3% of patients.Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HIV-1 and hepatitis B after discontinuation of emtricitabine or tenofovir and were associated with liver failure and liver decompensation in some of the emtricitabine-treated patients.Some of the postmarketing reports of hepatic failure with efavirenz occurred in patients with no preexisting liver disease or other identifiable risk factors.Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with nucleoside analogs.Hepatic steatosis and hepatitis have also been reported during postmarketing experience with tenofovir.
Common (1% to 10%): Elevated AST, elevated ALTEmtricitabine or tenofovir:-Common (1% to 10%): Elevated bilirubin-Frequency not reported: Severe acute exacerbations of hepatitis BEfavirenz:-Common (1% to 10%): Elevated ALT, elevated AST, elevated GGT-Uncommon (0.1% to 1%): Acute hepatitis-Postmarketing reports: Hepatic enzyme increase, hepatic failure (a few reports were characterized by a fulminant course, with some cases progressing to transplantation or death), hepatitisEmtricitabine:-Common (1% to 10%): Elevated serum AST and/or elevated serum ALT, hyperbilirubinemia-Frequency not reported: Liver failure, liver decompensationTenofovir:-Common (1% to 10%): Increased transaminases-Rare (less than 0.1%): Hepatic steatosis, hepatitis-Frequency not reported: Lactic acidosis/severe hepatomegaly with steatosis-Postmarketing reports: Elevated liver enzymes (primarily AST, ALT, GGT)
Decreased neutrophils (less than 750/mm3) has been reported in 3% of patients.
Common (1% to 10%): Decreased neutrophilsFrequency not reported: Increased hemoglobinEmtricitabine:-Common (1% to 10%): Neutropenia-Uncommon (0.1% to 1%): Anemia
Elevated creatine kinase (greater than 990 units/L in males and 845 units/L in females) has been reported in up to 9% of patients.Rhabdomyolysis, osteomalacia, muscular weakness, and myopathy may occur as a result of proximal renal tubulopathy.Rhabdomyolysis, osteomalacia, muscular weakness, and myopathy have also been reported during postmarketing experience with tenofovir.
Common (1% to 10%): Elevated creatine kinaseUncommon (0.1% to 1%): MyalgiaEmtricitabine or tenofovir:-Common (1% to 10%): Arthralgia, myalgiaEmtricitabine:-Very common (10% or more): Elevated creatine kinaseEfavirenz:-Postmarketing reports: Arthralgia, myalgia, myopathyTenofovir:-Uncommon (0.1% to 1%): Rhabdomyolysis, muscular weakness-Rare (less than 0.1%): Myopathy, osteomalacia (manifested as bone pain and infrequently contributing to fractures)-Frequency not reported: Decreased bone mineral density, increased biochemical markers of bone metabolismCombination antiretroviral therapy:-Frequency not reported: Osteonecrosis
Common (1% to 10%): HematuriaUncommon (0.1% to 1%): GlycosuriaTenofovir:-Uncommon (0.1% to 1%): Proteinuria-Postmarketing reports: Polyuria
Hematuria (greater than 75 red blood cells/high power field) and glycosuria (3+ or greater) have been reported in up to 3% and less than 1% of patients, respectively.Proteinuria has also been reported during postmarketing experience with tenofovir.
Tenofovir:-Uncommon (0.1% to 1%): Increased creatinine-Rare (less than 0.1%): Renal failure (acute and chronic), acute tubular necrosis, proximal renal tubulopathy (including Fanconi syndrome), nephrogenic diabetes insipidus-Frequency not reported: New onset or worsening renal impairment-Postmarketing reports: Renal insufficiency, nephritis (including acute interstitial nephritis)
Rhabdomyolysis, osteomalacia, hypokalemia, muscular weakness, myopathy, and hypophosphatemia may occur as a result of proximal renal tubulopathy.Renal failure, acute renal failure, Fanconi syndrome, proximal renal tubulopathy, increased creatinine, acute tubular necrosis, and nephrogenic diabetes insipidus have also been reported during postmarketing experience with tenofovir.
Frequency not reported: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)Efavirenz:-Postmarketing reports: Immune reconstitution syndromeEmtricitabine:-Postmarketing reports: Immune reconstitution syndromeTenofovir:-Postmarketing reports: Immune reconstitution syndrome
Efavirenz:-Uncommon (0.1% to 1%): Hypersensitivity-Postmarketing reports: Allergic reactionsEmtricitabine:-Common (1% to 10%): Allergic reactionTenofovir:-Postmarketing reports: Allergic reaction (including angioedema)
Efavirenz:-Frequency not reported: QT interval prolongation, torsades de pointes-Postmarketing reports: Palpitations
Efavirenz:-Uncommon (0.1% to 1%): GynecomastiaTenofovir:-Frequency not reported: Higher serum parathyroid hormone levels
Gynecomastia has also been reported during postmarketing experience with efavirenz.
Efavirenz:-Uncommon (0.1% to 1%): Blurred vision-Postmarketing reports: Abnormal vision
Blurred vision has also been reported during postmarketing experience with efavirenz.
Abdominal or stomach pain or tenderness
blistering, peeling, or loosening of the skin
body aches or pain
clay-colored stools
cough
dark urine
ear congestion
fever or chills
headache
itching
loss of voice
muscle aches
nausea and vomiting
severe skin rash
sore throat
swelling of the feet or lower legs
tightness of the chest
trouble concentrating
yellow eyes or skin
Diarrhea
dizziness
unusual tiredness or weakness
Abnormal dreams
decreased appetite
discouragement
feeling sad or empty
irritability
loss of appetite
loss of interest or pleasure
mild rash
pain or tenderness around the eyes and cheekbones
sleepiness
trouble sleeping
unusual drowsiness